Study With an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome | Clinical Trial - SERAPHIN


The goal of the trial was to evaluate the safety and efficacy of macitentan, a dual endothelin-receptor antagonist, in patients with pulmonary arterial hypertension (PAH).

Contribution to the Literature: The SERAPHIN trial showed that high and low doses of macitentan are safe and efficacious compared with placebo in improving hemodynamics, symptoms, and intermediate-term morbidity.